Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 1
1998 1
1999 2
2000 2
2001 2
2002 8
2003 2
2004 1
2005 3
2006 3
2008 6
2009 3
2010 3
2011 6
2012 3
2013 3
2014 4
2015 4
2016 5
2017 4
2018 3
2019 5
2020 6
2021 4
2022 3
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Gain of Chromosome 1q21"
Page 1
Multiple myeloma with high-risk cytogenetics and its treatment approach.
Hanamura I. Hanamura I. Int J Hematol. 2022 Jun;115(6):762-777. doi: 10.1007/s12185-022-03353-5. Epub 2022 May 9. Int J Hematol. 2022. PMID: 35534749 Free PMC article. Review.
Cytogenetic abnormalities (CAs) are the most widely accepted predictors for poor prognosis in multiple myeloma (MM), such as t(4;14), t(14;16), t(14;20), gain/amp(1q21), del(1p), and del(17p). ...
Cytogenetic abnormalities (CAs) are the most widely accepted predictors for poor prognosis in multiple myeloma (MM), such as t(4;14), …
Chromosome 1q21 abnormalities in multiple myeloma.
Schmidt TM, Fonseca R, Usmani SZ. Schmidt TM, et al. Blood Cancer J. 2021 Apr 29;11(4):83. doi: 10.1038/s41408-021-00474-8. Blood Cancer J. 2021. PMID: 33927196 Free PMC article. Review.
Gain of chromosome 1q (+1q) is one of the most common recurrent cytogenetic abnormalities in multiple myeloma (MM), occurring in approximately 40% of newly diagnosed cases. ...Although the identification of a clear pathogenic mechanism from +1q remains elusive, many …
Gain of chromosome 1q (+1q) is one of the most common recurrent cytogenetic abnormalities in multiple myeloma (MM), occurring …
Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.
Gao W, Jian Y, Du J, Li X, Zhou H, Zhang Z, Yang G, Wang G, Tian Y, Li Y, Wu Y, Fu W, Li J, Chen W. Gao W, et al. Cancer Med. 2020 Nov;9(21):7819-7829. doi: 10.1002/cam4.3254. Epub 2020 Sep 2. Cancer Med. 2020. PMID: 32881351 Free PMC article.
Moreover, when coexisting with t(11;14), patients with 1q21 gain showed a comparable survival to those without 1q21 gain. For patients treated with novel induction regimens followed by ASCT, 1q21 gain also conferred an inferior prognosis. …
Moreover, when coexisting with t(11;14), patients with 1q21 gain showed a comparable survival to those without 1q21 …
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma.
Mohan M, Gong Z, Ashby TC, Al Hadidi S, Thanendrarajan S, Schinke C, Alapat D, Shaughnessy JD Jr, Zhan F, van Rhee F, Sawyer JR, Tian E, Zangari M. Mohan M, et al. Cancer. 2023 Aug 15;129(16):2491-2498. doi: 10.1002/cncr.34895. Epub 2023 Jun 6. Cancer. 2023. PMID: 37282609
BACKGROUND: Chromosome 1 abnormalities in multiple myeloma (MM) are increasingly recognized as high risk-defining features. ...Although del(1p13.3) was detected in 220 (19.4%) patients, 1q21gain or 1q21amp were observed in 300 (26.5%) and 150 (13.2%) patients, respe …
BACKGROUND: Chromosome 1 abnormalities in multiple myeloma (MM) are increasingly recognized as high risk-defining features. ...Althou …
Clinical Characteristics and Prognosis of MAF Deletion in Chinese Patients With Multiple Myeloma.
Wang Y, Li Q, Xing S, Zhang H, Li D. Wang Y, et al. Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):e545-e550. doi: 10.1016/j.clml.2019.05.016. Epub 2019 May 29. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31262667
Patient samples were evaluated using a fluorescence in situ hybridization probe set, including 13q deletion, 17p deletion, and 1q21 gain, as well as immunoglobulin heavy chain gene (IgH) rearrangement, IgH/cyclin D1, IgH/fibroblast growth factor receptor 3 (FGFR3), …
Patient samples were evaluated using a fluorescence in situ hybridization probe set, including 13q deletion, 17p deletion, and 1q21 …
The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma.
Jin Y, Yu X, Du J, Li H, Tang W, Jia C, Zan Y, Chen M, Zhang Y, Yu M, Rong W, Zhou D, Zhuang J. Jin Y, et al. Ann Hematol. 2021 May;100(5):1251-1260. doi: 10.1007/s00277-021-04475-2. Epub 2021 Mar 8. Ann Hematol. 2021. PMID: 33686491
The prognostic value of chromosomal 1q21 gain in newly diagnosed multiple myeloma (NDMM) remains controversial. ...The combination of 1q21 gain and Myc rearrangement was associated with poorer overall survival than Myc rearrangement alone (16.8 …
The prognostic value of chromosomal 1q21 gain in newly diagnosed multiple myeloma (NDMM) remains controversial. ...The …
Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.
Wang YT, Bao L, Chu B, Chen XH, Lu MQ, Shi L, Gao S, Fang LJ, Xiang QQ, Ding YH. Wang YT, et al. J Clin Lab Anal. 2022 Jul;36(7):e24375. doi: 10.1002/jcla.24375. Epub 2022 Mar 30. J Clin Lab Anal. 2022. PMID: 35353920 Free PMC article.
INTRODUCTION: The gain/amplification (amp) of 1q21 is one of the most common high-risk chromosome abnormality (HRCA) in multiple myeloma (MM). ...NA vs. 83.5m) compared with gain 1q21 alone and no FISH abnormalities. Although the high ratio of p …
INTRODUCTION: The gain/amplification (amp) of 1q21 is one of the most common high-risk chromosome abnormality (HRCA) in …
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.
Shah V, Sherborne AL, Walker BA, Johnson DC, Boyle EM, Ellis S, Begum DB, Proszek PZ, Jones JR, Pawlyn C, Savola S, Jenner MW, Drayson MT, Owen RG, Houlston RS, Cairns DA, Gregory WM, Cook G, Davies FE, Jackson GH, Morgan GJ, Kaiser MF. Shah V, et al. Leukemia. 2018 Jan;32(1):102-110. doi: 10.1038/leu.2017.179. Epub 2017 Jun 6. Leukemia. 2018. PMID: 28584253 Free PMC article.
Through a meta-anlysis of these data with data from MRC Myeloma IX trial, totalling 1905 newly diagnosed MM patients (NDMM), we confirm the association of t(4;14), t(14;16), t(14;20), del(17p) and gain(1q21) with poor prognosis with hazard ratios (HRs) for OS of 1.6 …
Through a meta-anlysis of these data with data from MRC Myeloma IX trial, totalling 1905 newly diagnosed MM patients (NDMM), we confirm the …
The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event.
Locher M, Steurer M, Jukic E, Keller MA, Fresser F, Ruepp C, Wöll E, Verdorfer I, Gastl G, Willenbacher W, Weger R, Nachbaur D, Wolf D, Gunsilius E, Zschocke J, Steiner N. Locher M, et al. Am J Hematol. 2020 Dec;95(12):1562-1571. doi: 10.1002/ajh.25994. Epub 2020 Sep 19. Am J Hematol. 2020. PMID: 32936982 Free PMC article. Clinical Trial.
Hyperdiploidy (HRD) and specific immunoglobulin heavy locus (IGH) translocations are primary chromosomal abnormalities (CA) in multiple myeloma (MM). In this retrospective study of 794 MM patients we aimed to investigate clinical features and common CA including gain …
Hyperdiploidy (HRD) and specific immunoglobulin heavy locus (IGH) translocations are primary chromosomal abnormalities (CA) in multip …
Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Varma A, et al. Biol Blood Marrow Transplant. 2020 Apr;26(4):665-671. doi: 10.1016/j.bbmt.2019.12.726. Epub 2019 Dec 24. Biol Blood Marrow Transplant. 2020. PMID: 31881283 Free PMC article.
The gain/amplification CKS1B gene at chromosome region 1q21 (1q+) is one of the most common genetic aberrations in multiple myeloma (MM). ...Patients in the 1q+/1p- group were at significantly increased risk of progression or death compared to the control gro …
The gain/amplification CKS1B gene at chromosome region 1q21 (1q+) is one of the most common genetic aberrations in mult …
84 results